Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer, participants who are of cancer-free but may be at risk for triple-negative breast cancer, and for participants who are receiving adjuvant pembrolizumab following initial triple negative breast cancer treatment.


Clinical Trial Description

This is an open-label, phase I dose-escalation trial that will be performed on three successive cohorts. The first cohort is comprised of participants with high-risk triple-negative breast cancer. The second is made up of participants scheduled to undergo bilateral prophylactic mastectomy due to their genetic risk of triple-negative breast cancer. The third cohort is comprised of participants who have had treatment for their triple-negative breast cancer treatment, receiving adjuvant pembrolizumab. These cohorts will be treated with successively higher doses of α-lactalbumin and zymosan. This aLA breast cancer vaccine is an investigational (experimental) drug that the study team believes will work by stimulating the immune system to fight the participant's cancer, in a way similar to the way the immune system fights off an infection after a vaccination for that infection. α-lactalbumin Vaccine is experimental because it is not approved by the Food and Drug Administration (FDA). A traditional "3+3" Phase I trial design will be employed for the cohorts to determined the Maximum Tolerated Dose (MTD). After identification of the MTD, if at least 1 participant has an immunologic response (correlative measurement), successively lower dose levels will be expanded to a total of 6 participants and immunologic response assessed. Enrollment will stop if a dose level is reached for which no responses are observed. Dose-Limiting toxicities (DLTs) in 2 or more of 6 participants, the next lower dose will be considered the new MTD. Objectives are to determine MTD, DLT incidence, and Lowest Immunologic Dose (LID) for each cohort. Toxicity will be assessed every 2 weeks until day 56 and at day 84 or at off-study. Participants will be offered participation in long-term follow-up involving contact or in-person follow-up for late toxicity and survival every 3 months for 2 years, every 6 months for an additional 3 years, and then annually for 10 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04674306
Study type Interventional
Source Case Comprehensive Cancer Center
Contact George T Budd, MD
Phone 1-866-223-8100
Email TaussigResearch@ccf.org
Status Recruiting
Phase Early Phase 1
Start date October 1, 2021
Completion date September 1, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491694 - To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer Phase 2
Recruiting NCT06125080 - The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) :Single-arm, Prospective, Open Clinical Study Phase 2
Recruiting NCT05396612 - Role of the Immune Environment in Response to Therapy in Breast Cancer
Completed NCT03719326 - A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Phase 1
Recruiting NCT06230185 - ctDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting NCT05491226 - Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Phase 2
Withdrawn NCT05062174 - Breast Cancer BRCA1 Carriers: a Pilot Study
Recruiting NCT06059469 - PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03057600 - Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Phase 2
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Not yet recruiting NCT04755868 - Talazoparib Maintenance Therapy in Triple-negative Breast Cancer Phase 2
Recruiting NCT01042379 - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2
Recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Recruiting NCT05914961 - Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
Completed NCT05390710 - PhI to Solid Tumors and PhII to Locally Advanced or mTNBC Phase 1
Recruiting NCT05862064 - PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer Phase 3
Active, not recruiting NCT04395989 - An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. Phase 2